Skip to main content
  • English
  • Français
  • Español
  • Russian

Breadcrumb

  1. Home
  2. Gastroenterology
  3. Gut microbiota signature for cirrhosis
  • Our publications
    • News
    • Microbiota Mag
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • Partnerships
    • Press room
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
    • Xpeer App
  • Useful documents
    • Infographic
    About the Institute

    Join the microbiota community

    • Facebook
    • Twitter
    • YouTube

Lay public section

Find here your dedicated section
Gastroenterology
Gynecology
Pediatrics
Dermatology

Breadcrumb

  1. Home
  2. Gastroenterology
  3. Gut microbiota signature for cirrhosis
Gastroenterology

Gut microbiota signature for cirrhosis

Cirrhosis
Hepatology Gastroenterology

What if a stool analysis, potentially supplemented by a blood test, were enough to diagnose liver cirrhosis and distinguish it from fibrosis? The following study suggests this may be possible.

Gastroenterology
Gynecology
Pediatrics
Dermatology
  • Our publications
    • News
    • Microbiota Mag
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • Partnerships
    • Press room
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
    • Xpeer App
  • Useful documents
    • Infographic
    About the Institute

    Join the microbiota community

    • Facebook
    • Twitter
    • YouTube

Lay public section

Find here your dedicated section

Sources

This article is based on scientific information

Sharing is caring

Your colleagues might be interested in this topic. Why not share it?

  • Facebook
  • Twitter
  • Mail

About this article

Created 18 November 2020
Updated 31 March 2022

Non-alcoholic steatohepatitis (NASH) is thought to affect 24% of the world’s population and an alteration of the gut microbiota has been implicated in the progression from advanced fibrosis to cirrhosis. The stool microbiota of 163 US subjects was analyzed to determine the diagnostic capacity of this link. The participants included 54 non-NASH control subjects, 27 NASH patients suffering from cirrhosis (the most advanced stage of the disease) and their first-degree relatives. The results were supported by data from two independent Chinese and Italian cohorts.

Two independent signatures

The results showed a loss of bacterial diversity in the NASH-cirrhosis patients. This was found to be correlated with certain clinical parameters, notably LDL levels, coagulation, and blood insulin levels. More importantly, a (sidenote: Machine Learning Automatic learning whereby artificial intelligence solves a task based on metagenomic and metabolomic data collected, in this case the identification of discriminating bacterial species ) approach identified a bacterial signature for cirrhosis based on 19 species with a diagnostic accuracy of 0.91. This dysbiosis was associated with a functional signature, notably the biosynthesis of specific amino acids (aromatic and branched), fatty acids and nucleotides. These results, which were confirmed in independent cohorts, suggest that the dysregulation of essential microbial metabolic processes may contribute to the progression of the disease to cirrhosis. Therefore, altered metabolite production may explain how gut dysbiosis can affect the liver. To further support this potential causal link, an independent signature based on 17 metabolites was identified, which provided the same diagnostic accuracy as the microbial signature. Significant correlations were found between the two signatures.

Distinguishing cirrhosis from fibrosis

The researchers subsequently sought to refine this microbial signature. By also considering age and blood albumin levels, they slightly improved the signature’s precision in distinguishing cirrhosis patients from control subjects, and above all validated its effectiveness in the Chinese and Italian cohorts. Lastly, the inclusion of a highly discriminating additional parameter (increased levels of aspartate aminotransferase (AST) in the blood of cirrhosis patients) has made it possible to distinguish cirrhosis from early-stage mild to moderate fibrosis.

A non-invasive diagnostic tool or even a treatment?

The robustness of this intestinal signature across geographically and culturally distinct populations shows its potential as a diagnostic tool for cirrhosis. Some bacterial species in the gut microbiota may become a useful non-invasive and universal diagnostic tool, or even potential targets for new therapeutic approaches.

 

Sources

Oh TG, Kim SM, Caussy C et al. A Universal Gut-Microbiome-Derived Signature Predicts Cirrhosis. Cell Metab. 2020 Nov 3;32(5):901.

 

Tags
Cirrhosis Dysbiosis Hepatic cirrhosis Non-alcoholic steatohepatitis NASH Fibrosis Diagnosis Liver

en_view en_sources

    Created 18 November 2020
    Updated 31 March 2022

    About this article

    To know more about this topic.

    Main topic

    Cirrhosis

    Medical practice

    Hepatology Gastroenterology

    Content type

    News
    Gastroenterology

    The blue poop challenge: a reliable method to evaluate gut transit?

    By Pr. Gianluca Ianiro Gastroenterology Department, Fondazione Policlinico Universitario Agostino Gemelli- ...

    Find out more

    New perspectives in autism: the role of microbiota in social communication

    Overview By Dr. Vincent Trebossen Child and Adolescent P...

    Find out more

    Gut microbiota #15

    By Pr. Markku Voutilainen Turku University Faculty of Medicine; Turku University Hospital, Department of Ga...

    Find out more

    Microbiome topics at gastro 2021

    Congress Review By Pr. Eamonn M M Quigley Lynda K and David M Underwood Center for Digestive Disorders, Di...

    Find out more

    Commensal clostridiales strains mediate effective anti-cancer immune response against solid tumours

    Commented articles - Adults' section By Pr. Harry Sokol ...

    Find out more

    Microbiota in covid-19 pandemic

    Overview By Pr. Conceição Calhau NOVA Medical School, New University of Lisbon, Portugal By Pr. Pedro Povo...

    Find out more

    Association between fungal dysbiosis and environment

    The fungal portion of the gut microbiota (or mycobiota) has been much less studied than the bacterial porti...

    Find out more

    From diarrhea to chronic diseases: the well-documented consequences of antibiotic-related gut microbiota dysbiosis

    Antibiotic treatment may sometimes take place without any...

    Find out more

    Continue reading

    News
    Photo: Neonatal sepsis: the microbiota pays a heavy price for antibiotic use
    09.05.2022

    Neonatal sepsis: the microbiota pays a heavy price for antibiotic use

    Read the article
    26.04.2022

    Severe obesity: the vicious circle of biotin metabolism

    Read the article
    22.04.2022

    SCFAs: new intestinal markers of Parkinson’s disease?

    Read the article
    15.04.2022

    Multiple sclerosis and microbiota: does meat consumption play a role?

    Read the article
    08.04.2022

    Inflammatory Bowel Disease (IBD): do microplastics condition severity?

    Read the article
    04.04.2022

    The microbiota, a significant factor in smoking cessation

    Read the article
    30.04.2019

    The lingual microbiota, biomarker of pancreatic cancer?

    Read the article
    15.06.2021

    Autism: link between severity of the disorder and changes in the gut microbiota?

    Read the article
    What's worth reading about microbiota
    Follow us on Twitter
    Read our thematic folder
    The Janus face of Antibiotics: Life Savers & Microbiota Disrupters
    NL13_cover
    Check out latest newsletter
    IBS, Microbiota & Covid-19
    • Our publications
      • News
      • Microbiota Mag
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographic
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • YouTube

    Lay public section

    Find here your dedicated section
    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology
    • English
    • Français
    • Español
    • Russian

    Browse the site

    • Our publications
      • News
      • Microbiota Mag
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographic
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • YouTube

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology

    Join the microbiota community

    • Facebook
    • Twitter
    • YouTube

    Lay public section

    Find here your dedicated section

    en_redirection

    en_you_are_about_to_leave

    • en_be_redirected
    • en_stay_on_biocodex

    Stay with us !

    Join the Microbiota Community of HCPs and researchers and receive once a month the “Microbiota Digest” to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    Explore

    Photo: Neonatal sepsis: the microbiota pays a heavy price for antibiotic use
    09.05.2022

    Neonatal sepsis: the microbiota pays a heavy price for antibiotic use

    Read the article
    04.05.2022

    Miscarriage: Is vaginal dysbiosis a suspect?

    Read the article
    26.04.2022

    Severe obesity: the vicious circle of biotin metabolism

    Read the article

    Stay updated

    Join the Microbiota Community of HCPs and researchers and receive once a month the “Microbiota Digest” to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    • Our publications
      • News
      • Microbiota Mag
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographic
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • YouTube

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology

    Lay public section

    Find here your dedicated section

    Join the microbiota community

    • Facebook
    • Twitter
    • YouTube

    © 2022 Biocodex. All rights reserved.

    • Cookies Policy
    • Data protection policy
    • GTU
    • Sitemap
    • Cookies settings
    Biocodex logo